yingweiwo

Duloxetine ((S)-Duloxetine; LY248686)

Alias: LY248686; LY-227942; LY-248686; LY 227942; (S)-Duloxetine; (S)-Duloxetine; Yentreve; Cymbalta; (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; LY 248686; HSDB 7368; Duloxetine
Cat No.:V18170 Purity: ≥98%
Duloxetine ((S)-Duloxetine; LY248686; LY-248686) is a serotonin-norepinephrine reuptake inhibitor(SNRI, Ki = 4.6 nM) used for treatment of major depressive disorder and generalized anxiety disorder (GAD),fibromyalgia and neuropathic pain.
Duloxetine ((S)-Duloxetine; LY248686)
Duloxetine ((S)-Duloxetine; LY248686) Chemical Structure CAS No.: 116539-59-4
Product category: 5-HT Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
25mg
50mg
100mg
250mg
Other Sizes

Other Forms of Duloxetine ((S)-Duloxetine; LY248686):

  • (±)-Duloxetine hydrochloride ((Rac)-Duloxetine hydrochloride)
  • Duloxetine HCl (LY-248686 HCl)
  • Duloxetine-d7 (Duloxetine-d7)
  • Duloxetine metabolite Para-Naphthol Duloxetine
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description

Duloxetine ((S)-Duloxetine; LY248686; LY-248686) is a serotonin-norepinephrine reuptake inhibitor (SNRI, Ki = 4.6 nM) used for treatment of major depressive disorder and generalized anxiety disorder (GAD), fibromyalgia and neuropathic pain.

Biological Activity I Assay Protocols (From Reference)
Targets
serotonin reuptake; norepinephrine reuptake
ln Vitro
Duloxetine is a pretreat of norepinephrine reuptake and serotonin (5-HT). Duloxetine has a weaker inhibitory effect on dopamine reuptake when compared to its effects on 5-HT and norepinephrine reuptake. It also exhibits low binding affinity for other neurotransmitter receptors, such as opioid receptors, dopamine D2 receptors, adrenergic, muscarinic (nonselective), and histamine H1 receptors. More than 90% of duloxetine in human plasma is protein bound, according to in vitro research. A1-acid glycoprotein and albumin are the main targets of the binding[1].
ln Vivo
Maximum plasma concentration (Cmax) of duloxetine ranges from about 47 ng/mL (40 mg twice-daily dose) to 110 ng/mL (80 mg twice-daily dose) about 6 hours after dosing. Duloxetine has an elimination half-life of roughly 10–12 hours and a distribution volume of about 1640 L. After a 60 mg single dose, the absolute oral bioavailability ranged from 30% to 80% on average in one study and from 19% to 71% on average in another. Duloxetine absorption is influenced by food and time of day; food and bedtime administration cause a 4-hour tmax delay[1].
Cell Assay
Cell Viability Assay[2] Cells were seeded in 96-well plates at a density of 2 × 105 cells per well, grown for 24 h, and then treated with the drugs according to time-dependence or dose-dependence protocols. Each treatment was conducted in triplicate. After the drug treatments, the cell viability was assayed using a Cell Counting Kit-8 (CCK-8) according to the manufacturer’s instructions. CCK-8 uses the sensitive colorimetric WST-8 assay to determine the number of viable cells. WST-8 is a highly water-soluble tetrazolium salt, with the chemical designation of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt
Animal Protocol
Duloxetine and α-Adrenergic Receptor Antagonists Administration[3] Duloxetine was dissolved in distilled water (D.W.). Different doses of duloxetine (10, 30, and 60 mg/kg) were administered (i.p.). To test which adrenergic receptor subtypes mediated the anti-allodynic effects of duloxetine in oxaliplatin-administered mice, antagonists were administered intrathecally 20 min prior to duloxetine treatments. Non-selective α-adrenergic antagonists (phentolamine, 20 μg), α1-adrenergic receptor antagonists (prazosin, 10 μg), and α2-adrenergic receptor antagonists (idazoxan, 10 μg) were administered in volumes of 5 μL. The dose of each antagonist was determined based on previously conducted studies showing the selective and effective antagonistic action against adrenergic receptor-mediated responses.[3]
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Duloxetine is incompletely absorbed with a mean bioavailability of 50% although there is wide variability in the range of 30-80%. The population absorption constant (ka) is 0.168 h-1.The molecule is susceptible to hydrolysis in acidic environments necessitating the use of an enteric coating to protect it during transit through the stomach. This creates a 2 hour lag time from administration to the start of absorption. The Tmax is 6 hours including the lag time. Administering duloxetine with food 3 hour delay in Tmax along with an 10% decrease in AUC. Similarly, administering the dose at bedtime produces a 4 hour delay and 18% decrease in AUC with a 29% reduction in Cmax. These are attributed to delayed gastric emptying in both cases but are not expected to impact therapy to a clinically significant degree.
About 70% of duloxetine is excreted in the urine mainly as conjugated metabolites. Another 20% is present in the feces as the parent drug, 4-hydroxy metabolite, and an uncharacterized metabolite. Biliary secretion is thought to play a role due to timeline of fecal excretion exceeding the time expected of normal GI transit.
Apparent Vd of 1620-1800 L. Duloxetine crosses the blood-brain barrier and collects in the cerebral cortex at a higher concentration than the plasma.
There is a large degree of interindividual variation reported in the clearance of duloxetine with values ranging from 57-114 L/h. Steady state concentrations have still been shown to be dose proportional with a doubling of dose from 30 to 60 mg and from 60 to 120 mg producing 2.3 and 2.6 times the Css respectively.
Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Only trace (<1% of the dose) amounts of unchanged duloxetine are present in the urine. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces. Duloxetine undergoes extensive metabolism, but the major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.
Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state plasma concentrations are typically achieved after 3 days of dosing. Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP1A2 and CYP2D6.
Orally administered duloxetine hydrochloride is well absorbed. There is a median 2 hour lag until absorption begins (Tlag), with maximal plasma concentrations (Cmax) of duloxetine occurring 6 hours post dose. Food does not affect the Cmax of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (AUC) by about 10%. There is a 3 hour delay in absorption and a one-third increase in apparent clearance of duloxetine after an evening dose as compared to a morning dose. The apparent volume of distribution averages about 1640 L. Duloxetine is highly bound (>90%) to proteins in human plasma, binding primarily to albumin and a1-acid glycoprotein. The interaction between duloxetine and other highly protein bound drugs has not been fully evaluated. Plasma protein binding of duloxetine is not affected by renal or hepatic impairment.
Metabolism / Metabolites
Duloxetine is extensively metabolized primarily by CYP1A2 and CYP2D6 with the former being the greater contributor. It is hydroxylated at the 4, 5, or 6 positions on the naphthalene ring with the 4-hydroxy metabolite proceeding directly to a glucuronide conjugate while the 5 and 6-hydroxy metabolites proceed through a catechol and a 5-hydroxy, 6-methoxy intermediate before undergoing glucuronide or sulfate conjugation. CYP2C9 is known to be a minor contributor to the 5-hydroxy metabolite. Another uncharacterized metabolite is known to be excreted in the feces but comprises <5% of the total excreted drug. Many other metabolites exist but have not been identified due their low contribution to the overall profile of duloxetine and lack of clinical significance.
Biotransformation and disposition of duloxetine in humans have been determined following oral administration of (14C)-labeled duloxetine. Duloxetine comprises about 3% of the total radiolabeled material in the plasma, indicating that it undergoes extensive metabolism to numerous metabolites. The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP1A2 and CYP2D6 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate.
Duloxetine has known human metabolites that include 5-((S)-3-Methylamino-1-thiophen-2-yl-propoxy)-naphthalen-2-ol, 5-Hydroxyduloxetine, and 4-Hydroxyduloxetine.
The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.
Route of Elimination: Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces.
Half Life: 12 hours (range 8-17 hours)
Biological Half-Life
Mean of 12 h with a range of 8-17.
Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range.
Toxicity/Toxicokinetics
Toxicity Summary
IDENTIFICATION AND USE: Duloxetine hydrochloride is used for the acute management of generalized anxiety disorder in adults, the management of neuropathic pain associated with diabetic peripheral neuropathy in adults, the management of fibromyalgia in adults, the management of moderate to severe stress urinary incontinence (SUI) in women, and the acute and maintenance treatment of major depressive disorder in adults. HUMAN EXPOSURE AND TOXICITY: Possible risk of severe hepatic toxicity; elevated serum transaminase concentrations, sometimes requiring discontinuance of duloxetine, have been reported. In postmarketing experience, fatal outcomes have been reported for acute overdoses, primarily with mixed overdoses, but also with duloxetine only, at doses as low as 1000 mg. Signs and symptoms of overdose (duloxetine alone or with mixed drugs) included somnolence, coma, serotonin syndrome, seizures, syncope, tachycardia, hypotension, hypertension, and vomiting. A higher proportion of patients reporting discontinuation-emergent adverse events were seen with 120 mg/day duloxetine compared with lower doses. For doses between 40 and 120 mg/day duloxetine the proportion of patients reporting at least one discontinuation-emergent adverse event differed significantly from placebo. Extended treatment with duloxetine beyond 8-9 weeks did not appear to be associated with an increased incidence or severity of discontinuation-emergent adverse events. Abrupt discontinuation of duloxetine is associated with a discontinuation-emergent adverse event profile similar to that seen with other selective serotonin reuptake inhibitor (SSRI) and selective serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants ANIMAL STUDIES: Duloxetine was administered in the diet to mice for 2 years. In female mice receiving duloxetine at 140 mg/kg/day (6 times the maximum recommended human dose (MRHD) of 120 mg/day on a mg/ sq m basis), there was an increased incidence of hepatocellular adenomas and carcinomas. The no-effect dose was 50 mg/kg/day (2 times the MRHD). Tumor incidence was not increased in male mice receiving duloxetine at doses up to 100 mg/kg/day (4 times the MRHD). Duloxetine administered orally to either male or female rats prior to and throughout mating at doses up to 45 mg/kg/day (4 times the MRHD) did not alter mating or fertility. When duloxetine was administered orally to pregnant rats throughout gestation and lactation, the survival of pups to 1 day postpartum and pup body weights at birth and during the lactation period were decreased at a dose of 30 mg/kg/day (5 times the MRHD and 2 times the human dose of 120 mg/day on a mg/sq m basis); the no-effect dose was 10 mg/kg/day. Furthermore, behaviors consistent with increased reactivity, such as increased startle response to noise and decreased habituation of locomotor activity, were observed in pups following maternal exposure to 30 mg/kg/day. Post-weaning growth and reproductive performance of the progeny were not affected adversely by maternal duloxetine treatment. Duloxetine was not mutagenic in the bacterial reverse mutation assay (Ames test), and not clastogenic in an in vivo chromosomal aberration test in mouse bone marrow cells. Additionally, it was not genotoxic in an in vitro mammalian forward gene mutation assay in mouse lymphoma cells or in an in vitro unscheduled DNA assay in rat hepatocytes, and did not induce in vivo sister chromatid exchange assay in Chinese hamster bone marrow cells.
Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.
Toxicity Data
Oral, rat LD50: 491 mg/kg for males and 279 mg/kg for females (A308).
Interactions
Duloxetine is an inhibitor of the CYP1A2 isoform in in vitro studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1%-15%) and 20% (13%-27%) when co-administered with duloxetine (60 mg twice daily).
Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-administered with warfarin. Concomitant administration of warfarin (2-9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to 14 days in healthy subjects (n=15) did not significantly change INR from baseline (mean INR changes ranged from 0.05 to +0.07). The total warfarin (protein bound plus free drug) pharmacokinetics (AUCt,ss, Cmax,ss or tmax,ss) for both R- and S-warfarin were not altered by duloxetine. Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued.
Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and Cmax.
Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine).
When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the Cmax was increased about 2.5-fold, and duloxetine t1/2 was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin.
References

[1]. Clin Pharmacokinet . 2011 May;50(5):281-94.

[2]. Duloxetine-Induced Neural Cell Death and Promoted Neurite Outgrowth in N2a Cells. Neurotox Res. 2020 Dec;38(4):859-870.
[3]. Duloxetine Protects against Oxaliplatin-Induced Neuropathic Pain and Spinal Neuron Hyperexcitability in Rodents. Int J Mol Sci . 2017 Dec 5;18(12):2626.
Additional Infomation
Therapeutic Uses
Adrenergic Uptake Inhibitors; Analgesics; Antidepressive Agents; Dopamine Uptake Inhibitors; Serotonin Uptake Inhibitors
Duloxetine hydrochloride is used for the acute and maintenance treatment of major depressive disorder in adults.
Duloxetine has been used for the management of moderate to severe stress urinary incontinence (SUI) in women.
Duloxetine hydrochloride is used for the management of fibromyalgia in adults.
For more Therapeutic Uses (Complete) data for DULOXETINE (6 total), please visit the HSDB record page.
Drug Warnings
/BOXED WARNING/ WARNING: SUICIDAL THOUGHTS AND BEHAVIORS: Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.
Pregnancy Category C. Some neonates exposed to selective serotonin- and norepinephrine-reuptake inhibitors (SNRIs) or selective serotonin-reuptake inhibitors late in the third trimester of pregnancy have developed complications that have sometimes been severe and required prolonged hospitalization, respiratory support, enteral nutrition, and other forms of supportive care in special-care nurseries. Such complications can arise immediately upon delivery and usually last several days or up to 2-4 weeks. Clinical findings reported to date in the neonates have included respiratory distress, cyanosis, apnea, seizures, temperature instability or fever, feeding difficulty, dehydration, excessive weight loss, vomiting, hypoglycemia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, reduced or lack of reaction to pain stimuli, and constant crying. These clinical features appear to be consistent with either a direct toxic effect of the SNRI or selective serotonin-reuptake inhibitor or, possibly, a drug withdrawal syndrome. It should be noted that, in some cases, the clinical picture was consistent with serotonin syndrome (see Drug Interactions: Drugs Associated with Serotonin Syndrome, in Fluoxetine Hydrochloride 28:16.04.20). When treating a pregnant woman with duloxetine during the third trimester of pregnancy, the clinician should carefully consider the potential risks and benefits of such therapy. Consideration may be given to cautiously tapering duloxetine therapy in the third trimester prior to delivery if the drug is administered during pregnancy.
Potentially life-threatening serotonin syndrome reported with selective serotonin- and norepinephrine-reuptake inhibitors (SNRIs), including duloxetine, or selective serotonin-reuptake inhibitors (SSRIs), particularly with concurrent administration of other serotonergic drugs (e.g., serotonin [5-hydroxytryptamine; 5-HT] type 1 receptor agonists ["triptans"]) or drugs that impair serotonin metabolism (e.g., monoamine oxidase [MAO] inhibitors). Symptoms of serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or GI symptoms (e.g., nausea, vomiting, diarrhea). Concurrent therapy with MAO inhibitors used for treatment of depression is contraindicated. (See Drug Interactions: Monoamine Oxidase Inhibitors.) If concurrent therapy with duloxetine and a 5-HT1 receptor agonist is clinically warranted, the patient should be observed carefully, particularly during initiation of therapy, when dosage is increased, or when another serotonergic agent is initiated. Concomitant use of duloxetine and serotonin precursors (e.g., tryptophan) is not recommended.
Hepatic failure, sometimes fatal, has been reported in duloxetine-treated patients.The cases presented as hepatitis accompanied by abdominal pain, hepatomegaly, and markedly elevated serum transaminase concentrations (more than 20 times the upper limit of normal) with or without jaundice, reflecting a mixed or hepatocellular pattern of hepatic injury. Duloxetine should be discontinued in any patient who develops jaundice or other evidence of clinically important hepatic dysfunction; therapy should not be resumed unless another cause for the hepatic dysfunction can be established.
For more Drug Warnings (Complete) data for DULOXETINE (18 total), please visit the HSDB record page.
Pharmacodynamics
Duloxetine, through increasing serotonin and norepinephrine concentrations in Onuf's nucleus, enhances glutamatergic activation of the pudendal motor nerve which innervates the external urethral sphinter. This enhanced signaling allows for stronger contraction. Increased contraction of this sphincter increases the pressure needed to produce an incontinence episode in stress urinary incontinence. Duloxetine has been shown to improve Patient Global Impression of Improvement and Incontinence Quality of Life scores. It has also been shown to reduce the median incontinence episode frequency at doses of 40 and 80 mg. Action at the dorsal horn of the spinal cord allows duloxetine to strengthen the the serotonergic and adrenergic pathways involved in descending inhibition of pain. This results in an increased threshold of activation necessary to transmit painful stimuli to the brain and effective relief of pain, particularly in neuropathic pain. Pain relief has been noted in a variety of painful conditions including diabetic peripheral neuropathy, fibromyalgia, and osteoarthritis using a range of pain assessment surveys. While duloxetine has been shown to be effective in both animal models of mood disorders and in clinical trials for the treatment of these disorders in humans, the broad scope of its pharmacodynamic effects on mood regulation in the brain has yet to be explained. Increased blood pressure is a common side effect with duloxetine due to vasoconstriction mediated by the intended increase in norepinephrine signaling.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C18H19NOS
Molecular Weight
297.416
Exact Mass
297.12
CAS #
116539-59-4
Related CAS #
Duloxetine hydrochloride; 136434-34-9; Duloxetine-d7; 919514-01-5; (±)-Duloxetine hydrochloride; 947316-47-4; Duloxetine metabolite Para-Naphthol Duloxetine; 949095-98-1
PubChem CID
60835
Appearance
Typically exists as solid at room temperature
Density
1.2±0.1 g/cm3
Boiling Point
466.2±40.0 °C at 760 mmHg
Flash Point
235.7±27.3 °C
Vapour Pressure
0.0±1.2 mmHg at 25°C
Index of Refraction
1.628
LogP
3.73
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
6
Heavy Atom Count
21
Complexity
312
Defined Atom Stereocenter Count
1
SMILES
CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C3=CC=CS3
InChi Key
ZEUITGRIYCTCEM-KRWDZBQOSA-N
InChi Code
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
Chemical Name
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
Synonyms
LY248686; LY-227942; LY-248686; LY 227942; (S)-Duloxetine; (S)-Duloxetine; Yentreve; Cymbalta; (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; LY 248686; HSDB 7368; Duloxetine
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.3622 mL 16.8112 mL 33.6225 mL
5 mM 0.6724 mL 3.3622 mL 6.7245 mL
10 mM 0.3362 mL 1.6811 mL 3.3622 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors
CTID: NCT06711978
Phase: N/A    Status: Not yet recruiting
Date: 2024-12-02
The Back Pain Consortium Research Program Study
CTID: NCT04870957
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-11-29
Identifying and Treating Depression in the Orthopaedic Trauma Population
CTID: NCT05976347
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-11-27
Exercise Plus Duloxetine for Knee Osteoarthritis
CTID: NCT04111627
Phase: Phase 2    Status: Recruiting
Date: 2024-11-26
Duloxetine for LBP
CTID: NCT05851976
Phase: Phase 4    Status: Recruiting
Date: 2024-11-22
View More

Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization
CTID: NCT03548454
Phase: Phase 4    Status: Recruiting
Date: 2024-11-22


A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
CTID: NCT04504812
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-18
Effect of Combined Morphine and Duloxetine on Chronic Pain
CTID: NCT03249558
Phase: Phase 4    Status: Completed
Date: 2024-11-14
Microbiome Derived Metabolism and Pharmacokinetics
CTID: NCT05065671
Phase: Phase 1    Status: Recruiting
Date: 2024-11-14
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer
CTID: NCT06407401
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-11-05
Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain
CTID: NCT05311774
Phase: N/A    Status: Recruiting
Date: 2024-10-16
The BEST Trial: Biomarkers for Evaluating Spine Treatments
CTID: NCT05396014
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-10-15
SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.
CTID: NCT06614322
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-09-26
Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy
CTID: NCT04970121
Phase: Phase 2    Status: Recruiting
Date: 2024-09-25
Duloxetine to Prevent Chronic Postsurgical Pain After Inguinal Hernia Repair in Patients at High Risk
CTID: NCT06606067
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-09-20
Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
CTID: NCT03271151
Phase: Phase 4    Status: Completed
Date: 2024-09-19
ADC-induced Neurotoxicity Treated With Duloxetine
CTID: NCT06551051
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
CTID: NCT04245748
Phase: Phase 4    Status: Recruiting
Date: 2024-08-29
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
CTID: NCT04245436
Phase: Phase 4    Status: Recruiting
Date: 2024-08-29
Pain Response Evaluation of a Combined Intervention to Cope Effectively
CTID: NCT04395001
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-08-13
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
CTID: NCT05840562
Phase: Phase 3    Status: Recruiting
Date: 2024-08-02
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
CTID: NCT04137107
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-07-31
Evaluating the Efficacy and Safety of Preoperative Administration of Duloxetine for Pain Management in Women Undergoing Hysterectomy Via Vaginal Route
CTID: NCT06429605
Phase: N/A    Status: Recruiting
Date: 2024-07-26
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
CTID: NCT03511118
Phase:    Status: Recruiting
Date: 2024-07-24
Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis
CTID: NCT06245109
Phase: Phase 4    Status: Recruiting
Date: 2024-07-24
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
CTID: NCT04560673
Phase: Phase 2    Status: Recruiting
Date: 2024-07-19
Duloxetine RCT on Postop TKA Outcomes
CTID: NCT05086393
Phase: Phase 4    Status: Recruiting
Date: 2024-06-13
Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
CTID: NCT05851898
Phase: Phase 4    Status: Recruiting
Date: 2024-06-03
Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE)
CTID: NCT06423716
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-05-21
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
CTID: NCT03434041
Phase: Phase 3    Status: Completed
Date: 2024-04-26
Biomarkers for Prediction of Analgesic Efficacy in Knee OA.
CTID: NCT05256342
Phase: N/A    Status: Completed
Date: 2024-04-12
Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
CTID: NCT05120934
Phase: Phase 2    Status: Recruiting
Date: 2024-04-01
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
CTID: NCT05110144
Phase: Phase 2    Status: Recruiting
Date: 2024-04-01
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
CTID: NCT02893371
Phase:    Status: Terminated
Date: 2024-03-12
Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy
CTID: NCT05786599
Phase: Phase 2/Phase 3    Status: Not yet recruiting
Date: 2024-02-14
Study of Analgesic Action of Pregabalin, Duloxetine and Tramadol in Patients With Different Neuropathic Pain Phenotypes
CTID: NCT06252116
Phase:    Status: Recruiting
Date: 2024-02-09
Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder
CTID: NCT06232473
Phase: Phase 4    Status: Recruiting
Date: 2024-01-30
Duloxetine for PHN
CTID: NCT04313335
Phase: N/A    Status: Completed
Date: 2024-01-09
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
CTID: NCT04476030
Phase: Phase 3    Status: Completed
Date: 2023-12-22
Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)
CTID: NCT05560516
Phase: N/A    Status: Recruiting
Date: 2023-12-15
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
CTID: NCT02229825
Phase: Phase 4    Status: Completed
Date: 2023-10-23
Pain Relieving Potentials of Combination of Oral Duloxetine and Intravenous Magnesium Sulphate in Post Mastectomy Pain
CTID: NCT06087211
Phase: Phase 4    Status: Recruiting
Date: 2023-10-17
Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome
CTID: NCT06025474
Phase: Phase 3    Status: Recruiting
Date: 2023-09-06
The Effect of Central Sensitization on Treatment Response in Patients With Fibromyalgia
CTID: NCT05020600
Phase:    Status: Unknown status
Date: 2023-08-15
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
CTID: NCT05814640
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2023-08-14
The Effect of Preoperative Duloxetine on the Occurance of Postoperative Delirium in Patients Undergoing Cancer Surgery.
CTID: NCT05949229
Phase: Phase 1/Phase 2    Status: Not yet recruiting
Date: 2023-07-17
Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
CTID: NCT03575403
Phase: Phase 1    Status: Completed
Date: 2023-07-12
Duloxetine Combined With Intra-articular Injection of Corticosteroid and Hyaluronic Acid Reduces Pain in the Treatment of Knee Osteoarthritis Patients
CTID: NCT04117893
Phase: Phase 4    Status: Completed
Date: 2023-07-11
The Effect of Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Fibromyalgia
CTID: NCT05937711
Phase: N/A    Status: Completed
Date: 2023-07-10
Psychiatric Orders in Psychoanalytic Treatment of ASD
CTID: NCT05930912
Phase:    Status: Active, not recruiting
Date: 2023-07-05
Therapeutic Efficacy in Women With Stress Urinary Incontinence
CTID: NCT05677295
Phase: Phase 3    Status: Recruiting
Date: 2023-05-19
Neurobiology of Treatment Responses in MDD
CTID: NCT03068247
Phase: Phase 3    Status: Withdrawn
Date: 2023-04-24
Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee
CTID: NCT05486026
Phase: Phase 2    Status: Completed
Date: 2023-03-14
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
CTID: NCT04178993
Phase: Phase 1    Status: Completed
Date: 2023-01-09
Duloxetine Tibial Plateau
CTID: NCT04639011
Phase: Phase 4    Status: Withdrawn
Date: 2022-11-21
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
CTID: NCT04446039
Phase:    Status: Completed
Date: 2022-11-16
Duloxetine Impact on Postoperative Pain Control and Outcomes
CTID: NCT05611749
Phase: Phase 2    Status: Unknown status
Date: 2022-11-10
Duloxetine on Bone Metabolism
CTID: NCT05550506
Phase:    Status: Unknown status
Date: 2022-09-22
Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study
CTID: NCT04412876
Phase: Phase 3    Status: Withdrawn
Date: 2022-08-17
Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain
CTID: NCT00425230
Phase: N/A    Status: Terminated
Date: 2022-08-12
Efficacy of Pregabalin Vs Duloxetine in Diabetic Peripheral Neuropathic Pain at Variable Dose
CTID: NCT05292066
PhaseEarly Phase 1    Status: Unknown status
Date: 2022-08-04
The Cymbalta Pregnancy Registry
CTID: NCT01074151
Phase:    Status: Completed
Date: 2022-07-18
Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients
CTID: NCT04732455
Phase: N/A    Status: Completed
Date: 2022-07-11
Duloxetine for Postoperative Pain of Laparoscopic Cholecystectomy
CTID: NCT05115123
Phase: Phase 2    Status: Completed
Date: 2022-05-16
Antidepressant Response in Older Adults With Comorbid PTSD and MDD
CTID: NCT04697693
Phase: Phase 4    Status: Terminated
Date: 2022-05-11
The Clinical Effect of Pregabalin on Neuropathic Pain in Central Sensitized Patients After Total Knee Arthroplasty
CTID: NCT05254652
Phase: N/A    Status: Unknown status
Date: 2022-04-12
Efficacy of Pregabalin and Duloxetine in Patients With PDPN: the Effect of Pain on Cognitive Function, Sleep and Quality of Life
CTID: NCT04246619
Phase: Phase 4    Status: Terminated
Date: 2022-04-07
Botulinum Toxin Type A in Diabetic Peripheral Neuropathy
CTID: NCT05296759
Phase: Phase 4    Status: Completed
Date: 2022-04-06
A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
CTID: NCT02174822
Phase: Phase 1    Status: Completed
Date: 2022-02-18
A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain
CTID: NCT04224584
Phase: Phase 2    Status: Completed
Date: 2022-02-16
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
CTID: NCT05018013
Phase: Phase 2    Status: Unknown status
Date: 2021-11-12
Combination Pain Therapy in HIV Neuropathy
CTID: NCT00863057
Phase: Phase 2    Status: Terminated
Date: 2021-11-04
Duloxetine Role in Reducing Opioid Consumption After Thoracotomy
CTID: NCT03618225
Phase: Phase 4    Status: Completed
Date: 2021-10-14
Levomilnacipran in Healthy Males
CTID: NCT03249311
Phase: Phase 4    Status: Unknown status
Date: 2021-10-06
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
CTID: NCT02422186
Phase: Phase 3 St
Antidepressant treatments during pregnancy and lactation: prediction of drug exposure through breastfeeding and evaluation of drug effect on
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-11-03
Shifting pain modulation towards anti-nociceptivity: Mechanism-specific pharmacological prevention of post sternotomy pain: the MASTER study
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2015-05-20
Patient stratification and treatment response prediction in neuropharmacotherapy using PET/MR –
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-06-17
Effect of pre-operative pain treatment by means of duloxetine on postoperative outcome after total hip or knee arthroplasty
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2014-05-19
The effect of various medications on emotioal processing, attention, experiences and sensory information processing
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2013-02-15
Pain management in osteoarthritis using the centrally acting analgesics duloxetine and pregabalin
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-08-08
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects with Major Depressive Disorder (MDD)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-08-08
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression (TRD).
CTID: null
Phase: Phase 2    Status: Completed
Date: 2011-11-15
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-10-27
Effect of duloxetine and venlafaxine on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-09-08
A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients with Treatment Resistant Major Depression
CTID: null
Phase: Phase 2    Status: Completed
Date: 2011-07-08
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2011-04-06
Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiety Disorder
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-08-03
Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-07-13
Effectiveness of Transmural Collaborative care and Duloxetine for major depressive disorder and (sub)chronic pain: a randomized placebo-controlled Multi-Centre trial.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-07-01
A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with Major Depressive Disorder.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-05-11
Randomized Double-blind Study Comparing the Efficacy of Duloxetine with Placebo in Patients with Chronic Low Back Pain
CTID: null
Phase: Phase 2    Status: Completed
Date: 2010-05-06
Adherence of antidepressants during pregnancy
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-04-29
Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy “The COMBO - DN (COmbination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study”
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-03-10

CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-01-21
A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients with Major Depressive Disorder and Associated Painful Physical Symptoms
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-01-08
Skeletal muscle-derived cell implantation in female patients with stress urinary incontinence: a multicenter, randomized, parallel-group, placebo-controlled clinical study
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2009-12-18
Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects with Major Depressive Disorder
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-11-09
Efficacy, safety, tolerability and pharmacokinetics of concomitant administration of tramadol with duloxetine or pregabalin: a randomized controlled flexible-dose study in patients with neuropathic pain
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2009-07-14
“A Phase 4, 8-week, double-blind, randomized study comparing switching to duloxetine or escitalopram in patients with major depressive disorder and residual apathy in the absence of depressed mood.”
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-06-30
A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-06-29
Duloxetine 60 mg once daily versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-06-17
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-04-01
“TERAPIA ELECTROCONVULSIVA DE CONSOLIDACIÓN ASOCIADA A PSICOFÁRMACOS VERSUS FARMACOTERAPIA EN LA PREVENCIÓN DE RECIDIVAS EN EL TRASTORNO DEPRESIVO MAYOR. UN ENSAYO CLÍNICO, PRAGMÁTICO, PROSPECTIVO ALEATORIZADO”.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2009-02-04
Comparing Problem Solving Treatment combined with duloxetine with Problem Solving Treatment alone for patients with major depressive disorder in primary care
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-12-02
Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-11-19
EFFICACY OF DULOXETINE IN THE TREATMENT OF URINARY INCONTINENCEAFTER PROSTATECTOMIE DUE TO CANCER
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2008-11-18
A 12 weeks open label two parallel groups study to assess the efficacy of orally administered duloxetine 60 mg and 120 mg per day on treatment outcomes in patients with diabetic peripheral neuropatic pain with and without co-morbid major depressive disorder
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-10-20
Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-09-15
A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-09-02
Effect of Duloxetine 60 mg Once Daily versus Placebo in Patients with Chronic Low Back Pain
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-08-04
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects with Diabetic Neuropathic Pain
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-11-09
Influence of Duloxetin on C-fiber function and perception of deep somatic pain in major depression
CTID: null
Phase: Phase 3    Status: Completed
Date: 2007-08-02
Duloxetine 60 to 120 mg versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain
CTID: null
Phase: Phase 3    Status: Completed
Date: 2007-03-21
Pain, anxiety and depression in neuropathic and non-neuropathic pain: Effect of monoamine modulation.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2007-03-05
An open label pilot study on the tolerability of duloxetine in the treatment of depressed patients with Parkinson s disease
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-02-21
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-12-13
An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-12-11
A Double-blind, Randomised, Parallel Groups Investigation into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering from Diabetic Peripheral Neuropathy
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2006-11-08
Interozeptive Aufmerksamkeit, Hitze-Schwelle und körperliche Symptome bei Patienten mit einer depressiven Episode, vor und nach Behandlung mit Duloxetin.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2006-07-27
Efecto de la duloxetina en la respuesta nociceptiva cerebral en el trastorno depresivo mayor. Estudio mediante resonancia magnética funcional (RMf)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2006-03-06
Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-02-10
Chronos: Can the antidepressive response induced by sleep deprivation (wake-therapy) be sustained through continuous stabilisation of the diurnal rhythm and long term light treatment in patients with major depression treated with duloxetine?
CTID: null
Phase: Phase 4    Status: Completed
Date: 2005-09-05
.A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women ≥ 65 years of age with symptoms of stress urinary incontinence or stress–predominant mixed urinary incontinence.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2005-09-05
A double-blind, randomised, multicenter, comparative
CTID: null
Phase: Phase 4    Status: Completed
Date: 2005-06-30
Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-06-29
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-05-13
A ten-week, randomized, double-blind study evaluating the efficacy of Duloxetine 60 mg once daily versus placebo in outpatients with major depressive disorder and pain (EU-Pain enriched study)
CTID: null
Phase: Phase 4    Status: Completed
Date: 2005-05-10
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-03-03
Effect of Duloxetine on Valsalva Leak Point Pressure
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-02-24
A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2005-02-15
Open-Label Duloxetine Extension phase in Patients Who Have Completed the F1J-MC-HMDG Clinical Trial
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-01-27
Duloxetine 60 to 120 mg Once Daily Compared with
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-01-24
Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, dose-finding study of Lu AA24530 in Major Depressive Disorder
CTID: null
Phase: Phase 2    Status: Completed
Date:
A phase 3 clinical trial of duloxetine in children and adolescents with depressive disorder
CTID: jRCT2080223678
Phase:    Status: completed
Date: 2017-10-13
The efficacy of duloxetine for neuropathic pain a comparison of pregabalin
CTID: UMIN000028475
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2017-08-01
Comparative test on the occurrence rate of side effects accompanying duloxetine oral dosing timing
CTID: UMIN000026441
Phase:    Status: Complete: follow-up complete
Date: 2017-04-15
SuPerIoR antIdepressanT Effect of Duloxetine in Japanese patients with post-stroke depression
CTID: UMIN000024197
Phase:    Status: Pending
Date: 2016-09-27
Effect of serotonin-norepinephrine reuptake inhibitor on functional gastrointestinal disorder and evaluation of the brain function.
CTID: UMIN000023995
Phase:    Status: Complete: follow-up complete
Date: 2016-09-09
Effect of perioperative administration of a duloxetine on development of persistent postsurgical pain
CTID: UMIN000022327
Phase:    Status: Recruiting
Date: 2016-05-16
Efficacy of duloxetine for cancer patients with neuropathic pain: Doubleblind, Randomized, Placebo controlled, exploratory trial
CTID: UMIN000017647
Phase:    Status: Complete: follow-up complete
Date: 2015-05-21
The effect of duloxetine in depression of menopose women
CTID: UMIN000017278
Phase:    Status: Complete: follow-up complete
Date: 2015-04-25
None
CTID: jRCT1080222824
Phase:    Status:
Date: 2015-04-20
Effectiveness of duloxetine for chemotherapy-induced peripheral neuropathy : a prospective study.
CTID: UMIN000017096
Phase:    Status: Recruiting
Date: 2015-04-10
Efficacy of Duloxetine for VIPN (Vincristine-Induced Peripheral Neuropathy) Treatment
CTID: UMIN000016661
Phase: Phase III    Status: Complete: follow-up complete
Date: 2015-04-01
The evaluation of duloxetine effect f e.querySelector("font strong").innerText = 'View More' } else if(up_display === 'none' || up_display ===

Contact Us